LuckyLucky
2021-12-15
...
20 Stocks Moving in Wednesday's Pre-Market Session
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":607578925,"tweetId":"607578925","gmtCreate":1639572281932,"gmtModify":1639572282169,"author":{"id":4087558306753550,"idStr":"4087558306753550","authorId":4087558306753550,"authorIdStr":"4087558306753550","name":"LuckyLucky","avatar":"https://static.tigerbbs.com/7f6923176f885b4cc7c0299b6e1ec22e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>...</p></body></html>","htmlText":"<html><head></head><body><p>...</p></body></html>","text":"...","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/607578925","repostId":1153534649,"repostType":4,"repost":{"id":"1153534649","kind":"news","pubTimestamp":1639570541,"share":"https://www.laohu8.com/m/news/1153534649?lang=&edition=full","pubTime":"2021-12-15 20:15","market":"us","language":"en","title":"20 Stocks Moving in Wednesday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1153534649","media":"Benzinga","summary":"Gainers\n\nGalera Therapeutics, Inc. rose 17.7% to $3.18 in pre-market trading after BTIG upgraded the","content":"<p><b>Gainers</b></p>\n<ul>\n <li><b>Galera Therapeutics, Inc.</b> rose 17.7% to $3.18 in pre-market trading after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.</li>\n <li><b>SeaChange International, Inc.</b> rose 16.6% to $1.76 in pre-market trading after the company reported better-than-expected Q3 results.</li>\n <li><b>CF Acquisition Corp. VI</b> rose 11.5% to $12.55 in pre-market trading after Trump Media & Technology Group announced a partnership with Rumble. Rumble recently announced the execution of a definitive business combination agreement with CFVI.</li>\n <li><b>Biofrontera Inc.</b> rose 9.8% to $6.04 in pre-market trading after dipping more than 19% on Tuesday.</li>\n <li><b>Inpixon</b> rose 8.9% to $0.73 in pre-market trading. Inpixon recently said its board has authorized review of strategic alternatives.</li>\n <li><b>East Stone Acquisition Corporation</b> rose 8.4% to $14.63 in pre-market trading after declining 26% on Tuesday.</li>\n <li><b>Uxin Limited</b> rose 8.3% to $1.82 in pre-market trading. Uxin reported second-quarter FY22 revenue growth of 353% year-on-year to RMB345.9 million ($53.7 million).</li>\n <li><b>Mesoblast Limited</b> rose 8.2% to $4.51 in pre-market trading. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.</li>\n <li><b>Borr Drilling Limited</b> rose 7.7% to $1.65 in pre-market trading after declining over 4% on Tuesday..</li>\n <li><b>Li-Cycle Holdings Corp.</b> rose 6% to $11.50 in pre-market trading. Li-Cycle recently announced plans to increase hub facility's input processing capacity by over 40%.</li>\n <li><b>Tuniu Corporation</b> rose 5.7% to $1.02 in pre-market trading.</li>\n</ul>\n<p><b>Losers</b></p>\n<ul>\n <li><b>Sidus Space, Inc.</b> fell 14.1% to $10.47 in pre-market trading. Sidus Space shares jumped 144% on Tuesday after the company priced its IPO at $5 per share.</li>\n <li><b>Alzamend Neuro, Inc.</b> fell 10.1% to $2.77 in pre-market trading after jumping 28% on Tuesday.</li>\n <li><b>Idera Pharmaceuticals, Inc.</b> shares fell 9.8% to $0.7850 in pre-market trading.</li>\n <li><b>Adagio Therapeutics, Inc.</b> fell 9.2% to $6.59 in pre-market trading after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.</li>\n <li><b>MIND Technology, Inc.</b> shares fell 7.9% to $1.64 in pre-market trading. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.</li>\n <li><b>Legend Biotech Corporation</b> shares fell 7.3% to $45.00 in pre-market trading after the company reported an offering of $300 million in ADSs.</li>\n <li><b>BeiGene, Ltd.</b> fell 6.6% to $260.00 in pre-market trading. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.</li>\n <li><b>Livent Corporation</b> fell 6.6% to $23.69 in pre-market trading. Goldman Sachs downgraded Livent from Neutral to Sell and announced a $23 price target.</li>\n <li><b>Leslie's, Inc.</b> shares fell 5.6% to $20.33 in pre-market trading after the company reported an offering of 12.5 million shares of common stock via selling shareholders.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>20 Stocks Moving in Wednesday's Pre-Market Session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n20 Stocks Moving in Wednesday's Pre-Market Session\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 20:15 GMT+8 <a href=https://www.benzinga.com/news/21/12/24616764/20-stocks-moving-in-wednesdays-pre-market-session><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gainers\n\nGalera Therapeutics, Inc. rose 17.7% to $3.18 in pre-market trading after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/12/24616764/20-stocks-moving-in-wednesdays-pre-market-session\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BGNE":"百济神州","UXIN":"优信"},"source_url":"https://www.benzinga.com/news/21/12/24616764/20-stocks-moving-in-wednesdays-pre-market-session","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153534649","content_text":"Gainers\n\nGalera Therapeutics, Inc. rose 17.7% to $3.18 in pre-market trading after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.\nSeaChange International, Inc. rose 16.6% to $1.76 in pre-market trading after the company reported better-than-expected Q3 results.\nCF Acquisition Corp. VI rose 11.5% to $12.55 in pre-market trading after Trump Media & Technology Group announced a partnership with Rumble. Rumble recently announced the execution of a definitive business combination agreement with CFVI.\nBiofrontera Inc. rose 9.8% to $6.04 in pre-market trading after dipping more than 19% on Tuesday.\nInpixon rose 8.9% to $0.73 in pre-market trading. Inpixon recently said its board has authorized review of strategic alternatives.\nEast Stone Acquisition Corporation rose 8.4% to $14.63 in pre-market trading after declining 26% on Tuesday.\nUxin Limited rose 8.3% to $1.82 in pre-market trading. Uxin reported second-quarter FY22 revenue growth of 353% year-on-year to RMB345.9 million ($53.7 million).\nMesoblast Limited rose 8.2% to $4.51 in pre-market trading. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.\nBorr Drilling Limited rose 7.7% to $1.65 in pre-market trading after declining over 4% on Tuesday..\nLi-Cycle Holdings Corp. rose 6% to $11.50 in pre-market trading. Li-Cycle recently announced plans to increase hub facility's input processing capacity by over 40%.\nTuniu Corporation rose 5.7% to $1.02 in pre-market trading.\n\nLosers\n\nSidus Space, Inc. fell 14.1% to $10.47 in pre-market trading. Sidus Space shares jumped 144% on Tuesday after the company priced its IPO at $5 per share.\nAlzamend Neuro, Inc. fell 10.1% to $2.77 in pre-market trading after jumping 28% on Tuesday.\nIdera Pharmaceuticals, Inc. shares fell 9.8% to $0.7850 in pre-market trading.\nAdagio Therapeutics, Inc. fell 9.2% to $6.59 in pre-market trading after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.\nMIND Technology, Inc. shares fell 7.9% to $1.64 in pre-market trading. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.\nLegend Biotech Corporation shares fell 7.3% to $45.00 in pre-market trading after the company reported an offering of $300 million in ADSs.\nBeiGene, Ltd. fell 6.6% to $260.00 in pre-market trading. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.\nLivent Corporation fell 6.6% to $23.69 in pre-market trading. Goldman Sachs downgraded Livent from Neutral to Sell and announced a $23 price target.\nLeslie's, Inc. shares fell 5.6% to $20.33 in pre-market trading after the company reported an offering of 12.5 million shares of common stock via selling shareholders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1632,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/607578925"}
精彩评论